Maier 1985.

Study characteristics
Methods	Randomized controlled trial
Participants	People with active inflammatory bowel disease (ulcerative colitis n = 30, or Crohn's disease n = 30)
Interventions	Oral 5‐ASA, 0.5 g 3 times daily (n = 15) or oral SASP, 1.0 g 3 times daily (n = 15) for 8 weeks
Outcomes	Remission and clinical improvement
Notes	Study also enrolled 30 participants with Crohn's disease Funding support and conflicts of interest were not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not described
Other bias	Unclear risk	Not described